Physician profile
James David Mcgee
NPI 1932669256
$4,708.64
in general payments reported to CMS, 2019-2025
25 companies · $2,865 in 2025
The $2,865 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $227 · 2023: $213 · 2024: $1,403 · 2025: $2,865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,481.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,859.42 | 2023-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $365.25 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $352.40 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| La Jolla Pharmaceutical Company | $226.15 | 2024-2025 | Giapreza |
| Merck Sharp & Dohme LLC | $211.62 | 2022-2024 | Dificid, Recarbrio, Zerbaxa |
| Pulmonx Corporation | $177.40 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.20 | 2025 | Ofev |
| Octapharma USA, INC. | $139.29 | 2024 | Balfaxar |
| Abiomed | $135.96 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2025 | Veklury |
| Csl Behring | $124.99 | 2025 | Kcentra |
| Viatris Specialty LLC | $124.98 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $120.29 | 2024 | |
| Shionogi INC | $118.60 | 2025 | Fetroja |
| Mallinckrodt Hospital Products INC. | $117.78 | 2025 | Terlivaz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.10 | 2024-2025 | Glassia |
| Pfizer INC. | $71.20 | 2022-2023 | |
| Amgen INC. | $35.46 | 2025 | Tezspire |
| Inspire Medical Systems, INC. | $33.55 | 2025 | Inspire |
| Genzyme Corporation | $31.07 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $28.87 | 2022-2023 | Xarelto |
| Mylan Specialty L.P. | $19.80 | 2024 | Yupelri |
| Harmony Biosciences LLC | $18.40 | 2025 | |
| Inquis Medical, INC. | $18.13 | 2024 | |
| United Therapeutics Corporation | $14.73 | 2023 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.